1. Introduction {#sec1-nanomaterials-09-00699}
===============

In the past decade, the utilization of magnetic iron oxide (Fe~3~O~4~) nanoparticles as a *T*~1~-weighted contrast for magnetic resonance imaging (MRI) has received tremendous attention \[[@B1-nanomaterials-09-00699],[@B2-nanomaterials-09-00699],[@B3-nanomaterials-09-00699],[@B4-nanomaterials-09-00699],[@B5-nanomaterials-09-00699],[@B6-nanomaterials-09-00699]\]. On the one hand, Fe~3~O~4~ nanoparticles have better biocompatibility compared to currently widely-used clinical Gd-chelate *T*~1~ contrast agents, such as Gd-DTPA and Gd-DTOA \[[@B7-nanomaterials-09-00699],[@B8-nanomaterials-09-00699],[@B9-nanomaterials-09-00699],[@B10-nanomaterials-09-00699],[@B11-nanomaterials-09-00699],[@B12-nanomaterials-09-00699]\]. The Gd-chelates have great potential accumulative toxicity (e.g., nephrogenic systemic fibrosis) caused by the leaching out of the Gd ions from the chelate ligand \[[@B13-nanomaterials-09-00699]\], while the Fe~3~O~4~ nanoparticles can be degraded in the body and the released iron ions can be subsequently incorporated into iron pools and metabolic processes \[[@B10-nanomaterials-09-00699]\]. On the other hand, Fe~3~O~4~ nanoparticles with a small size and suitable surface state are able to display a high longitudinal relaxation rate (*r*~1~) \[[@B14-nanomaterials-09-00699],[@B15-nanomaterials-09-00699],[@B16-nanomaterials-09-00699],[@B17-nanomaterials-09-00699],[@B18-nanomaterials-09-00699]\], which can significantly improve the spatial resolution of the *T*~1~-weighted image for some special sites such as blood vessels and vascular organs. Nevertheless, small Fe~3~O~4~ nanoparticles without appropriate ligands decorated on the surface tend to form aggregation and subsequently display *T*~2~ rather than *T*~1~ contrast enhancement \[[@B19-nanomaterials-09-00699],[@B20-nanomaterials-09-00699]\].

To improve the *T*~1~ contrast performance and prevent the aggregation of nanoparticles in vivo, great efforts have recently been focused on the synthesis and surface modification of Fe~3~O~4~ nanoparticles \[[@B21-nanomaterials-09-00699],[@B22-nanomaterials-09-00699],[@B23-nanomaterials-09-00699],[@B24-nanomaterials-09-00699],[@B25-nanomaterials-09-00699]\]. The coprecipitation reaction of Fe^2+^ and Fe^3+^ ions under alkaline conditions is a traditional and widely-used method to fabricate Fe~3~O~4~ nanoparticles \[[@B26-nanomaterials-09-00699],[@B27-nanomaterials-09-00699],[@B28-nanomaterials-09-00699],[@B29-nanomaterials-09-00699],[@B30-nanomaterials-09-00699]\]. Compared with some other methods, such as thermal decomposition \[[@B31-nanomaterials-09-00699],[@B32-nanomaterials-09-00699],[@B33-nanomaterials-09-00699]\] and hydrothermal and solvothermal methods \[[@B34-nanomaterials-09-00699],[@B35-nanomaterials-09-00699],[@B36-nanomaterials-09-00699],[@B37-nanomaterials-09-00699]\], coprecipitation is more convenient since it can be carried out in water phase without the further requirement of surfactant modification to improve the water-dispersibility of the obtained nanoparticles. Besides, similar to the approach of microwave-assisted synthesis \[[@B6-nanomaterials-09-00699],[@B38-nanomaterials-09-00699]\], the coprecipitation method is a procedure that can be easily scaled up \[[@B39-nanomaterials-09-00699]\]. However, because the reaction is carried out in water phase and the reaction speed is very fast for coprecipitation, controlling the size and preventing the aggregation of the produced Fe~3~O~4~ nanoparticles are always important and challenging issues \[[@B40-nanomaterials-09-00699]\]. Using functional macromolecule ligands as templates and stabilizers has proved to be an effective approach to overcome these challenges \[[@B37-nanomaterials-09-00699],[@B39-nanomaterials-09-00699],[@B40-nanomaterials-09-00699],[@B41-nanomaterials-09-00699],[@B42-nanomaterials-09-00699]\]. The affinity coordination groups, such as the hydroxyl and carboxylic acid groups from the macromolecule ligands, can coordinate with the iron ions and thus control the growth of the nanoparticle seed and prevent the aggregation of the produced nanoparticles \[[@B43-nanomaterials-09-00699]\]. For example, Rui et al. used poly(acrylic acid) to synthesize Fe~3~O~4~ nanoparticles with a small size and high relaxivity for in vivo *T*~1~-weighted imaging \[[@B39-nanomaterials-09-00699]\]. Li et al. developed poly(acrylic acid)-poly(methacrylic acid) for the synthesis of small Fe~3~O~4~ nanoparticles with good water-dispersibility and remarkable *T*~1~ contrast performance \[[@B26-nanomaterials-09-00699]\].

To date, a great number of macromolecule ligands have been utilized as templates and stabilizers to fabricate hydrophilic small Fe~3~O~4~ nanoparticles as *T*~1~ contrast agents \[[@B26-nanomaterials-09-00699],[@B27-nanomaterials-09-00699],[@B44-nanomaterials-09-00699],[@B45-nanomaterials-09-00699],[@B46-nanomaterials-09-00699]\], but studies that concern the use of different charges and coordination groups of macromolecule ligands are still limited \[[@B47-nanomaterials-09-00699],[@B48-nanomaterials-09-00699]\]. Indeed, the charges of macromolecule ligands are also an important parameter for controlling the size and preventing the aggregation of the Fe~3~O~4~ nanoparticles, since they usually correspond to the coordination affinity between the coordination groups and metal ions, and the electrostatic interaction between adjacent nanoparticles. In this work, we used three macromolecule ligands that possessed negative, positive and neutral charges with carboxylic acid, amino and hydroxyl groups, respectively, as templates and stabilizers for the coprecipitation synthesis of small magnetic Fe~3~O~4~ nanoparticles ([Scheme 1](#nanomaterials-09-00699-sch001){ref-type="scheme"}), which showed differences in size, water-dispersibility, cytotoxicity and *T*~1~-weight contrast performance.

2. Materials and Methods {#sec2-nanomaterials-09-00699}
========================

2.1. Materials {#sec2dot1-nanomaterials-09-00699}
--------------

Fe(SO~4~)~2~·7H~2~O, FeCl~3~·6H~2~O and NH~3~ solution (25%) were obtained from Sigma Aldrich (Saint Louis, MO, USA). Poly(allylamine hydrochloride) (PAH, average Mw \~ 17,500), poly(acrylic acid) (PAA, average Mw \~ 2000) and polyvinyl alcohol (PVA, average Mw \~ 20,000--30,000) were purchased from Alfa (Heysham, UK). All chemicals were used without further purification.

2.2. Synthesis of Fe~3~O~4~-PAH, Fe~3~O~4~-PAA and Fe~3~O~4~-PVA Nanoparticles {#sec2dot2-nanomaterials-09-00699}
------------------------------------------------------------------------------

The synthetic procedures for Fe~3~O~4~-PAH, Fe~3~O~4~-PAA and Fe~3~O~4~-PVA nanoparticles were quite similar, excepting the use of different polymer ligands as templates and stabilizers. Typically, the polymer ligand (140 mg) was added to a 250 mL three-necked flask with 50 mL of deionized water, and then stirred for 1 h under N~2~ atmosphere to remove the oxygen in the flask. Then 0.25 mmol of Fe(SO~4~)~2~·7H~2~O (70 mg) and 0.52 mmol of FeCl~3~·6H~2~O (140 mg) were dissolved in 2 mL of deionized water, and injected into the three-necked flask. The above mixture was slowly heated to 90 °C, and then 5 mL of concentrated ammonia solution was rapidly injected under vigorous stirring. The reaction was kept at 90 °C for a further 2 h and then cooled down to room temperature. The black suspension was ultrafiltration centrifugation (with 10-k ultra-filtration centrifuge tube) and was washed with deionized water 3--4 times.

2.3. Characterization {#sec2dot3-nanomaterials-09-00699}
---------------------

The structure of the obtained Fe~3~O~4~ nanoparticles was determined by Powder X-ray diffractometer (PXRD, Bruker, D8 ADVANCE, Cu K-α, Brucker, Karlsruhe, Germany). To verify the macromolecule ligand coating, Fourier-transform IR spectra (Nicolet Avatar 370 FT-IR, Thermo Electron Corporation, Madison, WI, USA) with potassium bromide as pressed pellets was carried out on a Nicolet Avatar 370 FT-IR spectrophotometer. The hydrodynamic size and zeta potential studies were carried out on a Malvern Zetasizer Nano ZS (Malvern, UK, scattering angle, 90°; temperature, 25 °C; refraction indexes of H~2~O and Fe~3~O~4~, 1.33 and 2.30, respectively). The morphology and size were evaluated using transmission electron microscopy (JEOL JEM-2010 microscopy, JEOL, Tokyo, Japan). The magnetic properties were measured using a superconducting quantum interference device (Lake Shore (Carson, CA, USA)). The concentration of nanoparticles was determined by dissolution in concentrated nitric acid (15 mol/L) and then ironion concentration was measured using high-dispersion inductively coupled plasma atomic emission spectroscopy (Teledyne Leeman Labs, Prodigy, Inc., Hudson, NH, USA). The longitudinal and transverse relaxation times (*T*~1~ and *T*~2~, respectively) for calculating the relaxation rate (*r*~1~ and *r*~2~, respectively) were measured on a magnetic resonance scanner (0.5 T, NMI20, Niumag, Shanghai, China) with parameters of DRG1, 3; TW, 8000 ms; RG, 20 db; SW, 100 kHz; SF, 18 MHz. *T*~1~-weighted images were obtained with the parameters of TR, 300 ms; TE, 0.04 ms; and *T*~2~-weighted images were acquired with parameters of TR, 4500 ms; TE, 100 ms.

2.4. In Vitro Cytotoxicity Assay {#sec2dot4-nanomaterials-09-00699}
--------------------------------

The cytotoxicity of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA nanoparticles were evaluated using standard methyl thiazolyltetrazolium (MTT) assay with 4T1 cell lines (a mouse breast cancer cell line). The 4T1 cells were purchased from Shanghai Institutes for Biological Sciences. The MTT assay was carried out according to the following procedures. 4T1 cells (5 × 10^4^ cells/well) were first plated in a 96-well plate for 24 h and then treated with different concentrations (0, 5, 12.5, 25, 50, and 100 μg/mL) of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, or Fe~3~O~4~-PVA nanoparticles in dulbecco's modified eagle medium (DMEM) for 12 or 24 h at 37 °C with 5% CO~2~. After that the medium was removed and the cells were washed with phosphate buffered saline (PBS), and then 20 μL (5 mg/mL) of thiazolyl blue tetrazolium bromide was added and the cells were incubated for a further 4 h. The medium was carefully removed and the remaining purple formazan crystals were lysed with 150 μL of dimethyl sulfoxide. The absorption of the formazan at 490 nm for calculating the cell viability was measured using a Multiskan MK3 microplate reader (Thermo Fisher Scientific, Waltham, MA, USA).

2.5. In Vivo Magnetic Resonance Imaging {#sec2dot5-nanomaterials-09-00699}
---------------------------------------

To evaluate in vivo the MRI properties of Fe~3~O~4~-PAA and Fe~3~O~4~-PVA, *T*~1~-weighted images of mice bearing 4T1 tumor were carried out on a 1.0 T MRI scanner (NM42-040H-I; Niumag, Shanghai, China). The intravenous injecting dose of materials was 1.3 mg Fe/kg body weight. During imaging, the mice were anesthetized with 8% chloral hydrate. The *T*~1~-weighted imaging parameters were the following: field of view, 100 × 100 mm; slice thickness, 3 mm; echo time, 20 ms; repetition time (TR), 300 ms; matrix size, 256 × 192 mm. The operations of all animal methods were carried out strictly according to the requirements of the Animal Ethics Committee of the Shanghai Normal University (approval code No: 2018-0127).

3. Results and Discussion {#sec3-nanomaterials-09-00699}
=========================

3.1. Synthesis and Characterization {#sec3dot1-nanomaterials-09-00699}
-----------------------------------

Giving that poly(acrylic acid) (PAA), poly(allylamine hydrochloride) (PAH), and polyvinyl alcohol (PVA) possess negative, positive and neutral charges with carboxylic acid, amino and hydroxyl coordination groups respectively, we used them as templates and stabilizers to fabricate Fe~3~O~4~ nanoparticles (denoted as Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA, respectively) through the coprecipitation reaction \[[@B49-nanomaterials-09-00699]\]. Typically, FeCl~3~, Fe(SO~4~)~2~ and PAA/PAH/PVA were mixed in deionized water and heated to 90 °C under a nitrogen atmosphere. Concentrated ammonia solution (25%) that served as the alkali was injected into the mixture to trigger the formation of Fe~3~O~4~ nanoparticles. In the beginning, the aqueous solution of iron ions and PAA, PAH or PVA were tawny and opaque. The pH of PAA, PAH and PVA in aqueous solution was 2.9, 5.8 and 3.8, respectively, and upon addition of ferric/ferrous salt, the corresponding pH changed to 1.5, 2.2 and 2.0, respectively. After the addition of concentrated ammonia solution, the reaction mixture became black immediately, suggested the formation of Fe~3~O~4~ nanoparticles.

Transmission electron microscopy (TEM) images showed that the average diameters of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA nanoparticles were 4.5 ± 0.8 and 7.4 ± 1.3 and 2.8 ± 0.4 nm, respectively ([Figure S1](#app1-nanomaterials-09-00699){ref-type="app"}). The slightly different sizes of the nanoparticles indicated the different capabilities of PAA, PAH and PVA as templates and stabilizers in controlling the growth of the Fe~3~O~4~ seeds. The crystalline structures and phase composition of the as-synthesized nanoparticles were characterized via X-ray diffraction (XRD). As shown in [Figure 1](#nanomaterials-09-00699-f001){ref-type="fig"}d, Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA have similar diffraction peaks, suggesting that they are all crystalline, which is important for magnetic nanoparticles. The 2-theta peaks at 30.4, 35.8, 43.5, 53.9, 57.5 and 63.2° were able to be indexed to {311}, {222}, {400}, {422}, {511} and {440} lattice planes of the cubic phase Fe~3~O~4~ (JCPDS No. 75-1449). No other peaks that belonged to this phase were observed for the three samples, confirming the successful fabrication of the pure phase Fe~3~O~4~. Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA exhibited good solubility in the aqueous solution ([Figure 1](#nanomaterials-09-00699-f001){ref-type="fig"}e). The hydrodynamic size of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA determined by dynamic light scattering (DLS) were around 56, 229 and 141 nm, respectively ([Figure S2](#app1-nanomaterials-09-00699){ref-type="app"}). Compared to the size observed from the TEM images, the larger hydrodynamic size of Fe~3~O~4~-PAA can be attributed to the surrounding macromolecule ligands and water molecules on the surface of the nanoparticles. Nevertheless, the hydrodynamic size of Fe~3~O~4~-PAH and Fe~3~O~4~-PVA were obviously larger than that observed in TEM images, suggesting the slight aggregation of Fe~3~O~4~-PAH and Fe~3~O~4~-PVA in the aqueous solution. The zeta potential of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA was determined to be −35.8, 39.0, and −1.1 mV, respectively ([Figure 2](#nanomaterials-09-00699-f002){ref-type="fig"}b). The negative, positive and nearly neutral zeta potential of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA were consistent with that of the PAA, PAH and PVA (−19.2, 25, and −0.83 mV, respectively), indicating the existence of macromolecule ligands on the surface of the nanoparticles.

The surface functionalization of the Fe~3~O~4~ nanoparticles with PAA, PAH and PVA ligands was further confirmed by Fourier transform infrared (FT-IR) spectrum. As shown in [Figure 2](#nanomaterials-09-00699-f002){ref-type="fig"}a, Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA exhibited a characteristic absorption peak of around 564--610 cm^−1^, which arose from the vibration band of Fe--O, suggesting the formation of Fe~3~O~4~. For PAA and Fe~3~O~4~-PAA, the absorption bands around 3200--3600 cm^−1^ can be attributed to the O--H stretching vibrations. The characteristic absorption peaks at 1712 and 1401 cm^−1^ were due to the C=O stretching vibrations and C--O stretching vibrations of carboxylic acid groups in the PAA, respectively \[[@B39-nanomaterials-09-00699]\]. The characteristic absorption bands for PAH and Fe~3~O~4~-PAH were observed at 3402, 3023 and 1604 cm^−1^, and can be attributed to the N--H stretching and bending vibrations, respectively. The absorption peak at 1113 cm^−1^ was due to the C--N stretching vibration \[[@B50-nanomaterials-09-00699]\]. For PVA and Fe~3~O~4~-PVA, characteristic absorption peaks were observed around 3200--3600 cm^−1^ (O--H stretching vibrations), 2940 cm^−1^ (--CH~2~-- symmetric vibrations), 1094 and 1438 cm^−1^ (C--O stretching vibrations) \[[@B51-nanomaterials-09-00699]\]. The characteristic absorption of PAA, PAH and PVA can be observed in that of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA, respectively, demonstrating the presence of macromolecules with the nanoparticles.

To evaluate whether the obtained Fe~3~O~4~ nanoparticles were superparamagnetic, which is crucial for magnetic Fe~3~O~4~ to be used as a *T*~1~-weighted MRI contrast agent, the magnetization curves for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA with a magnetic field up to 1.5 T were measured at 298 K. The saturation magnetization for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA were determined to be 32.1, 55.2 and 32.5 emu/g, respectively ([Figure 2](#nanomaterials-09-00699-f002){ref-type="fig"}c). The inductively coupled plasma-atomic emission spectrometry (ICP-AES) results revealed that the ratios of Fe~3~O~4~ to the total weight were 70.1% for Fe~3~O~4~-PAA, 73.6% for Fe~3~O~4~-PAH, and 44.6% for Fe~3~O~4~-PVA. Compared with Fe~3~O~4~-PAH, the Fe~3~O~4~-PAA and Fe~3~O~4~-PVA with smaller diameters exhibited lower saturation magnetization, which can be ascribed to the higher specific surface associated with spin-canting \[[@B52-nanomaterials-09-00699]\]. According to the hysteresis loops, the coercivity and remanence for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA were all negligible at room temperature, indicating their superparamagnetic behavior.

3.2. Magnetic Resonance Imaging {#sec3dot2-nanomaterials-09-00699}
-------------------------------

To assess the MRI properties of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA, the *T*~1~-weighted image and longitudinal and transverse relaxation time (*T*~1~ and *T*~2~, respectively) with different concentrations of materials in aqueous solution at 25 °C were studied using a 0.5 T MRI scanner. As shown in [Figure 3](#nanomaterials-09-00699-f003){ref-type="fig"}d, with the increasing concentration of materials, all the *T*~1~-weighted images of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA gradually brightened, indicating that they were able to exhibit *T*~1~-weighted contrast \[[@B45-nanomaterials-09-00699]\]. According to the slope of the relaxometric curves ([Figure 3](#nanomaterials-09-00699-f003){ref-type="fig"}a--c), the longitudinal molar relaxivities (*r*~1~) for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA were calculated to be 23.6, 60.8, and 30.9 mM s^−1^, respectively, which are relatively high values as compared to some reported relaxivities for Fe~3~O~4~ nanoparticles using similar synthesis methods \[[@B53-nanomaterials-09-00699]\]. The high *r*~1~ relaxivity of these nanoparticles should be attributed to their small size and high surface decorated with hydrophilic macromolecules, which can facilitate the water exchange rate between the surrounding bulk water molecules, and which coordinated with the Fe ions. The transverse molar relaxivities (*r*~2~) for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA were determined to be 62.3, 232.3 and 224.5 mM s^−1^, respectively. Generally, the *r*~2~/*r*~1~ ratio is a crucial parameter for assessing the *T*~1~ performance of contrast agents. The *r*~2~/*r*~1~ ratio for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA was calculated to be 2.64, 3.82 and 7.27, respectively. For Fe~3~O~4~-PAA, the low *r*~2~ and *r*~2~/*r*~1~ ratio indicated that it is adequate as a *T*~1~-weighted contrast agent.

3.3. In Vitro Cytotoxicity {#sec3dot3-nanomaterials-09-00699}
--------------------------

Encouraged by the good *T*~1~ contrast performance of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA, their biocompatibility was assessed before in vivo tests. The cytotoxicity of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA were investigated using 4T1 cell lines with standard methyl thiazolyltetrazolium (MTT) assay. For Fe~3~O~4~-PAA and Fe~3~O~4~-PVA, no significant cytotoxicity was observed after incubation with a different concentration of nanoparticles (0--100 μg mL^−1^ based on Fe) for 12 and 24 h. For Fe~3~O~4~-PAH, a significant decrease in the cell viability was observed even with very low concentrations of material. As shown in [Figure 4](#nanomaterials-09-00699-f004){ref-type="fig"}a,c, the 4T1 cell that incubated with Fe~3~O~4~-PAA and Fe~3~O~4~-PVA remained viable above 94% and 84%, respectively, when the concentration of Fe ions was up to 100 μg mL^−1^ and the incubation time was prolonged to 24 h, indicating lower cytotoxicity for Fe~3~O~4~-PAA and Fe~3~O~4~-PVA within the investigated concentration. Nevertheless, the cells that were incubated with Fe~3~O~4~-PAH had a viability of only about 8%, although the concentration of Fe ions was only 25 μg mL^−1^ and the incubation time was only 12 h, suggesting a very large cytotoxicity of Fe~3~O~4~-PAH ([Figure 4](#nanomaterials-09-00699-f004){ref-type="fig"}b). Generally, the cytotoxicity of a nanomaterial is associated with the surface properties of the nanoparticles. For Fe~3~O~4~-PAA, the low cytotoxicity of our results was in agreement with those reported in the literature, which showed that PAA-coated magnetic nanoparticles with highly negative zeta potential have good biocompatibility and are not internalized by biological cells \[[@B54-nanomaterials-09-00699]\]. For Fe~3~O~4~-PAH, the large cytotoxicity may be attributed to the abundant amino groups that have a high pKa value (around 9) of the PAH ligand on the surface of the Fe~3~O~4~ nanoparticles \[[@B48-nanomaterials-09-00699]\]. Due to the large cytotoxicity of Fe~3~O~4~-PAH, only Fe~3~O~4~-PAA and Fe~3~O~4~-PVA were used for further in vivo *T*~1~ MRI investigation.

3.4. In Vivo Magnetic Resonance Imaging {#sec3dot4-nanomaterials-09-00699}
---------------------------------------

The *T*~1~-weight images with 4T1 tumor-bearing mice as the model were studied on a 1 T MRI scanner. Before intravenous injection of the materials, *T*~1~-weight images of the coronal planes as control groups were acquired on the MRI scanner, and then the mice were intravenously injected with Fe~3~O~4~-PAA/Fe~3~O~4~-PVA with a dose of 1.3 mg Fe/kg body weight, and acquired the *T*~1~-weight at different time points. As shown in [Figure 5](#nanomaterials-09-00699-f005){ref-type="fig"}a, compared with the control group, the mice tumor and kidney sites brightened after 30 min, and gradually brightened with increasing time, suggesting Fe~3~O~4~-PAA displayed *T*~1~-weight contrast enhancement in these sites. To quantify the contrast, the signal-to-noise ratio was calculated through analyzing the target sites and the normal tissues of the *T*~1~-weight image. As shown in [Figure 5](#nanomaterials-09-00699-f005){ref-type="fig"}b,c, after intravenous injection of Fe~3~O~4~-PAA, the relative signal-to-noise ratio of the tumor site reached the maximum (increased to about 65%) at 160 min, and that of the kidney site reached the maximum (increased to about 49%) at 60 min and remained almost unchanged for about 100 min. The increased *T*~1~ signals at the tumor and kidney sites can be attributed to the accumulation of Fe~3~O~4~-PAA nanoparticles that instinctively featured *T*~1~ contrast enhancement at these sites. After 180 min, the relative signal-to-noise ratio of both the tumor and kidney sites decreased slowly, indicating the metabolism of the nanoparticles. These results demonstrated that Fe~3~O~4~-PAA should be a good *T*~1~-weight contrast agent for in vivo MR imaging.

Similar to Fe~3~O~4~-PAA, the *T*~1~-weight images of 4T1 tumor-bearing mice slightly brightened the contrast enhancement at the tumor and kidney sites after intravenous injection of Fe~3~O~4~-PVA for 40 min ([Figure 6](#nanomaterials-09-00699-f006){ref-type="fig"}a). The *T*~1~-weight signal reached the increased maximum of about 53% at 120 min for the tumor site ([Figure 6](#nanomaterials-09-00699-f006){ref-type="fig"}b), and 17% at 120 min for the kidney site ([Figure 6](#nanomaterials-09-00699-f006){ref-type="fig"}c), indicating that the Fe~3~O~4~-PVA were slowly accumulated and displayed *T*~1~ contrast enhancement in these sites. After 180 min, the relative signal-to-noise ratio of both tumor and kidney sites decreased slowly, suggesting the slow metabolism of the Fe~3~O~4~-PVA nanoparticles. The brightened contrast of the mice tumor and kidney sites demonstrated that Fe~3~O~4~-PVA can also be used as *T*~1~-weight MRI contrast agent. Nevertheless, the increased *T*~1~-weight signals at the tumor and kidney sites after intravenous injection of Fe~3~O~4~-PVA were slightly weaker than that for Fe~3~O~4~-PAA, indicating that Fe~3~O~4~-PAA would be a better *T*~1~-weight contrast agent.

4. Conclusions {#sec4-nanomaterials-09-00699}
==============

In summary, Fe~3~O~4~ nanoparticles with the surface modified by negative, positive and neutral macromolecule ligands of PAA, PAH and PVA, respectively, were synthesized using the coprecipitation reaction. The obtained Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA nanoparticles showed slight differences in size and water-dispersibility. Besides, Fe~3~O~4~ nanoparticles modified with PAA and PVA showed good biocompatibility, while those modified using PAH displayed high cytotoxicity during cell viability assay. In vitro and in vivo experiments demonstrated that both Fe~3~O~4~-PAA and Fe~3~O~4~-PVA are adequate as *T*~1~-weighted contrast agents, but Fe~3~O~4~-PAA exhibited a better *T*~1~ contrast performance. This work highlights that the macromolecule ligands for modifying the Fe~3~O~4~ nanoparticles greatly affect their biocompatibility and *T*~1~ contrast performance, which should be helpful for the design of functional ligands for developing Fe~3~O~4~ based *T*~1~ contrast agents.

The following are available online at <https://www.mdpi.com/2079-4991/9/5/699/s1>, Figure S1: Particle size distribution of (a) Fe~3~O~4~-PAA, (b) Fe~3~O~4~-PAH and (c) Fe~3~O~4~-PVA acquired from the TEM images. Figure S2: The hydrodynamic size profile of (a) Fe~3~O~4~-PAA, (b) Fe~3~O~4~-PAH and (c) Fe~3~O~4~-PVA nanoparticles in aqueous suspension.
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Figures and Scheme
==================

![Schematic illustration of the coprecipitation synthesis of Fe~3~O~4~-poly(acrylic acid) (PAA), Fe~3~O~4~-poly(allylamine hydrochloride) (PAH), and Fe~3~O~4~-polyvinyl alcohol (PVA) with negative, positive and neutral charges, respectively, as the *T*~1~-weight contrast agent.](nanomaterials-09-00699-sch001){#nanomaterials-09-00699-sch001}

![TEM images of (**a**) Fe~3~O~4~-PAA, (**b**) Fe~3~O~4~-PAH, and (**c**) Fe~3~O~4~-PVA. (**d**) PXRD of the Fe~3~O~4~ powder standard with JCPDS Card No. of 75-1449, Fe~3~O~4~-PAA, Fe~3+~O~4~-PAH and Fe~3~O~4~-PVA. (**e**) Photographs of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH and Fe~3~O~4~-PVA nanoparticles in aqueous suspension.](nanomaterials-09-00699-g001){#nanomaterials-09-00699-f001}

![(**a**) FTIR spectroscopy and (**b**) Zeta potential of Fe~3~O~4~-PAA, PAA, Fe~3~O~4~-PAH, PAH, Fe~3~O~4~-PVA and PVA. (**c**) Field-dependent magnetization curves for Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA nanoparticles at 298 K.](nanomaterials-09-00699-g002){#nanomaterials-09-00699-f002}

![Plot of 1/*T* against Fe concentration for (**a**) Fe~3~O~4~-PAA, (**b**) Fe~3~O~4~-PAH, and (**c**) Fe~3~O~4~-PVA nanoparticles. The values of *r*~1~and *r*~2~ were calculated based on the slopes of the corresponding fitting lines (B~0~ = 1 T, 25 °C). The *T*~1~° and *T*~2~° values of pure water were 2.79 and 3.01 s, respectively. (**d**) *T*~1~-weight MR images of the aqueous dispersion of Fe~3~O~4~-PAA, Fe~3~O~4~-PAH, and Fe~3~O~4~-PVA nanoparticles with different Fe concentrations.](nanomaterials-09-00699-g003){#nanomaterials-09-00699-f003}

![MTT assay of 4T1 cell viability after incubation of (**a**) Fe~3~O~4~-PAA, (**b**) Fe~3~O~4~-PAH and (**c**) Fe~3~O~4~-PVA at different concentrations of Fe for 12 and 24 h.](nanomaterials-09-00699-g004){#nanomaterials-09-00699-f004}

![(**a**) *T*~1~-weighted MR images (B~0~ = 1 T) of mice collected before (control group) and after intravenous injection of Fe~3~O~4~-PAA at time points of 30, 60, 90, 120, 160 and 180 min. The corresponding relative *T*~1~-weighted signals extracted from (**b**) tumor (orange circle) and (**c**) kidney (dark yellow circle) sites.](nanomaterials-09-00699-g005){#nanomaterials-09-00699-f005}

![(**a**) *T*~1~-weighted MR images (B~0~ = 1 T) of mice collected before (control group) and after intravenous injection of Fe~3~O~4~-PVA at time points of 40, 90, 120 and 180 min. The corresponding relative *T*~1~-weighted signals extracted from (**b**) tumor (orange circle) and (**c**) kidney (dark yellow circle) sites.](nanomaterials-09-00699-g006){#nanomaterials-09-00699-f006}
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